AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2007 | 617.38 Thousand USD | -15.98% |
| 2006 | 734.77 Thousand USD | -54.75% |
| 2005 | 1.62 Million USD | -3.98% |
| 2004 | 1.69 Million USD | 81.69% |
| 2003 | 930.72 Thousand USD | 20.76% |
| 2002 | 770.74 Thousand USD | 110.2% |
| 2001 | -7.55 Million USD | -1317.09% |
| 2000 | -533.37 Thousand USD | -144.45% |
| 1999 | 1.2 Million USD | 700.0% |
| 1998 | -200 Thousand USD | 0.0% |
| 1997 | -200 Thousand USD | -100.0% |
| 1996 | -100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2008 Q2 | 96.43 Thousand USD | -19.72% |
| 2008 Q1 | 120.11 Thousand USD | -62.25% |
| 2008 Q3 | 199.8 Thousand USD | 107.2% |
| 2007 FY | 617.38 Thousand USD | -15.98% |
| 2007 Q1 | 144.54 Thousand USD | -31.84% |
| 2007 Q2 | 58.76 Thousand USD | -59.34% |
| 2007 Q3 | 95.87 Thousand USD | 63.14% |
| 2007 Q4 | 318.19 Thousand USD | 231.87% |
| 2006 Q1 | 147.36 Thousand USD | -54.32% |
| 2006 Q3 | 96.17 Thousand USD | -65.55% |
| 2006 FY | 734.77 Thousand USD | -54.75% |
| 2006 Q4 | 212.06 Thousand USD | 120.49% |
| 2006 Q2 | 279.17 Thousand USD | 89.44% |
| 2005 Q3 | 349.94 Thousand USD | 55.95% |
| 2005 Q2 | 224.39 Thousand USD | -69.12% |
| 2005 FY | 1.62 Million USD | -3.98% |
| 2005 Q1 | 726.74 Thousand USD | 33.07% |
| 2005 Q4 | 322.61 Thousand USD | -7.81% |
| 2004 Q1 | 347.7 Thousand USD | 787.46% |
| 2004 Q4 | 546.12 Thousand USD | 88.53% |
| 2004 Q3 | 289.67 Thousand USD | -42.93% |
| 2004 Q2 | 507.55 Thousand USD | 45.97% |
| 2004 FY | 1.69 Million USD | 81.69% |
| 2003 Q1 | 228.61 Thousand USD | 4.93% |
| 2003 FY | 930.72 Thousand USD | 20.76% |
| 2003 Q3 | 369.69 Thousand USD | -3.48% |
| 2003 Q4 | -50.57 Thousand USD | -113.68% |
| 2003 Q2 | 383 Thousand USD | 67.53% |
| 2002 Q4 | 217.86 Thousand USD | 113.42% |
| 2002 FY | 770.74 Thousand USD | 110.2% |
| 2002 Q1 | -1.67 Million USD | -4.17% |
| 2002 Q3 | -1.62 Million USD | 6.88% |
| 2002 Q2 | -1.74 Million USD | -3.86% |
| 2001 Q4 | -1.61 Million USD | 26.1% |
| 2001 Q3 | -2.18 Million USD | -23.05% |
| 2001 Q2 | -1.77 Million USD | 11.17% |
| 2001 FY | -7.55 Million USD | -1317.09% |
| 2001 Q1 | -1.99 Million USD | -1035.95% |
| 2000 Q3 | -18.7 Thousand USD | 87.64% |
| 2000 Q4 | 213.11 Thousand USD | 1239.61% |
| 2000 FY | -533.37 Thousand USD | -144.45% |
| 2000 Q2 | -151.28 Thousand USD | -0.68% |
| 2000 Q1 | -150.26 Thousand USD | -111.56% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q1 | - USD | -100.0% |
| 1999 Q4 | 1.3 Million USD | 0.0% |
| 1999 FY | 1.2 Million USD | 700.0% |
| 1998 Q1 | - USD | -100.0% |
| 1998 FY | -200 Thousand USD | 0.0% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | -100.0% |
| 1997 FY | -200 Thousand USD | -100.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | -100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 25412.997% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 94.726% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 293.23% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.482% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 102.393% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1379.314% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 596.885% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 95.884% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -19802.772% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 93.696% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -839.301% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1907.859% |
| Mesoblast Limited | -35.16 Million USD | 101.756% |
| Marizyme, Inc. | 457.7 Thousand USD | -34.888% |
| Genus plc | 178.7 Million USD | 99.655% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.72% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -892.164% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -50.521% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 5712.582% |
| ContraFect Corporation | -154 Thousand USD | 500.899% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1334.768% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -704.294% |
| IMV Inc. | -962.29 Thousand USD | 164.157% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 259.324% |
| MultiCell Technologies, Inc. | 49.32 USD | -1251692.376% |
| ONE Bio Corp. | 20.12 Million USD | 96.932% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.467% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1162.544% |
| Q BioMed Inc. | -8988.00 USD | 6968.981% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 97.815% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 4102.749% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 98.608% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 154.082% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -781.977% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 12567.367% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -339.419% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 733.117% |
| GB Sciences, Inc. | -624.00 USD | 99039.744% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 817.655% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 296919.231% |
| Enzolytics Inc. | 30.7 Thousand USD | -1910.499% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -27.973% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.944% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 219.995% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.849% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 7071.364% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 836.305% |
| Kadimastem Ltd | -630.13 Thousand USD | 197.976% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 37.511% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 93.576% |
| BioStem Technologies, Inc. | 15.42 Million USD | 95.997% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 5316.595% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -249.674% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -249.674% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 54.509% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 2228.91% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -37.183% |
| SYBLEU INC | 11.69 Thousand USD | -5178.591% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 86.602% |
| Bioxytran, Inc. | -8285.00 USD | 7551.829% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 265.518% |
| Neutra Corp. | 14.33 Thousand USD | -4206.829% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 852.907% |
| PureTech Health plc | -1.6 Million USD | 138.514% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 161.662% |
| IXICO plc | 3.27 Million USD | 81.12% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 188.96% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 134.471% |
| CSL Limited | 7.7 Billion USD | 99.992% |
| Cellectis S.A. | 18 Thousand USD | -3329.911% |